Evidence map›Paper›PMID 32481766›Full record

ArticleMarine drugs2020

Novel Fredericamycin Variant Overproduced by a Streptomycin-resistant

Marta Rodríguez Estévez, Maksym Myronovskyi, Birgit Rosenkränzer, Thomas Paululat, Lutz Petzke, Jeanette Ristau, Andriy Luzhetskyy

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Identification of Antimicrobial Compounds in TwoFrontiers in microbiology · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marta Rodríguez EstévezPharmazeutische Biotechnologie, Universität des Saarlandes, 66123 Saarbrücken, Germany.
Maksym MyronovskyiPharmazeutische Biotechnologie, Universität des Saarlandes, 66123 Saarbrücken, Germany.
Birgit RosenkränzerPharmazeutische Biotechnologie, Universität des Saarlandes, 66123 Saarbrücken, Germany.
Thomas PaululatOrganische Chemie II, Universität Siegen, 57068 Siegen, Germany.
Lutz PetzkeBASF SE, 67056 Ludwigshafen, Germany.
Jeanette RistauBASF SE, 67056 Ludwigshafen, Germany.
Andriy LuzhetskyyPharmazeutische Biotechnologie, Universität des Saarlandes, 66123 Saarbrücken, Germany.
Saarland University · DEBASF (Germany) · DEFolkwang University of the Arts · DE

Funding

Bundesministerium für Bildung und Forschung 031B0868A
6 · The paper itself

Abstract

Streptomycetes are an important source of natural products potentially applicable in the pharmaceutical industry. Many of these drugs are secondary metabolites whose biosynthetic genes are very often poorly expressed under laboratory cultivation conditions. In many cases, antibiotic-resistant mutants exhibit increased production of natural drugs, which facilitates the identification and isolation of new substances. In this study, we report the induction of a type II polyketide synthase gene cluster in the marine strain

Indexed as

AlkenesAnti-Bacterial AgentsAquatic OrganismsBiological ProductsChromatography, High Pressure LiquidHumansIsoquinolinesMagnetic Resonance SpectroscopyStreptomycesStructure-Activity RelationshipAlkenesAnti-Bacterial AgentsBiological Productsfredericamycin CIsoquinolinesantitumorfredericamycinoverproductionsecondary metabolitesstreptomycetesstreptomycin-resistanttype II PKS

Identifiers

PMID32481766
PMCPMC7345809
OpenAlexW3030340651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.